COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE
Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non-valvular atrial fibrillation (NVAF) during preparation for elective cardioversion. Material and methods. An open non-randomized study was conducted to evaluate direct medical costs (cost of drug, cost of the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/98 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839641559944921088 |
|---|---|
| author | L. E. Kuvshinova N. V. Furman P. V. Dolotovskaya Ya. P. Dovgalevsky |
| author_facet | L. E. Kuvshinova N. V. Furman P. V. Dolotovskaya Ya. P. Dovgalevsky |
| author_sort | L. E. Kuvshinova |
| collection | DOAJ |
| description | Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non-valvular atrial fibrillation (NVAF) during preparation for elective cardioversion. Material and methods. An open non-randomized study was conducted to evaluate direct medical costs (cost of drug, cost of the international normalized ratio (INR) adjust- ment in outpatient clinic, cost of visits to cardiologist). Patients (n=62) with persistent NVAF (AF paroxysm duration > 48 hours) were enrolled. All of them requested medical as- sistance and were decided to perform an elective cardioversion. The patients received warfarin (n=32) or dabigatran (n=30). The patients of the both groups were similar in the main clinical characteristics and thromboembolic risk levels according to CHA2DS2-VASc scale.Results. Treatment duration before elective cardioversion was 21±2 and 30.5±4.5 days for dabigatran and warfarin groups, respectively (p<0.05). Average costs of visits to cardiologists were 3,720 and 744 RUB in warfarin and dabigatran groups, respectively (p<0.05), and drug costs were 53.63 and 1,172.01 RUB, respectively (p<0.05). The costs of laboratory INR monitoring were 3,058 RUB in warfarin group. Total costs per patient were 6,831.63 and 1,916.01 RUB in warfarin and dabigatran groups, respectively (p<0.05). Conclusion. In the real clinical practice in patients with NVAF dabigatran antithromboembolic therapy substantially reduces direct medical costs in comparison with warfarin ther- apy during preparation for elective cardioversion. Dabigatran therapy reduces time from the decision of elective cardioversion and antithromboembolic therapy start to car- dioversion performance. |
| format | Article |
| id | doaj-art-0e2d997b55af4dc18c2bfc5fb1d4da8c |
| institution | Matheson Library |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-0e2d997b55af4dc18c2bfc5fb1d4da8c2025-07-03T07:28:21ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-019439840310.20996/1819-6446-2013-9-4-398-40397COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICEL. E. Kuvshinova0N. V. Furman1P. V. Dolotovskaya2Ya. P. Dovgalevsky3Saratov Research Institute of Cardiology, SaratovSaratov Research Institute of Cardiology, SaratovSaratov Research Institute of Cardiology, SaratovSaratov Research Institute of Cardiology, Saratov State Medical University named after V.I. Razumovsky, SaratovAim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non-valvular atrial fibrillation (NVAF) during preparation for elective cardioversion. Material and methods. An open non-randomized study was conducted to evaluate direct medical costs (cost of drug, cost of the international normalized ratio (INR) adjust- ment in outpatient clinic, cost of visits to cardiologist). Patients (n=62) with persistent NVAF (AF paroxysm duration > 48 hours) were enrolled. All of them requested medical as- sistance and were decided to perform an elective cardioversion. The patients received warfarin (n=32) or dabigatran (n=30). The patients of the both groups were similar in the main clinical characteristics and thromboembolic risk levels according to CHA2DS2-VASc scale.Results. Treatment duration before elective cardioversion was 21±2 and 30.5±4.5 days for dabigatran and warfarin groups, respectively (p<0.05). Average costs of visits to cardiologists were 3,720 and 744 RUB in warfarin and dabigatran groups, respectively (p<0.05), and drug costs were 53.63 and 1,172.01 RUB, respectively (p<0.05). The costs of laboratory INR monitoring were 3,058 RUB in warfarin group. Total costs per patient were 6,831.63 and 1,916.01 RUB in warfarin and dabigatran groups, respectively (p<0.05). Conclusion. In the real clinical practice in patients with NVAF dabigatran antithromboembolic therapy substantially reduces direct medical costs in comparison with warfarin ther- apy during preparation for elective cardioversion. Dabigatran therapy reduces time from the decision of elective cardioversion and antithromboembolic therapy start to car- dioversion performance.https://www.rpcardio.online/jour/article/view/98atrial fibrillationcardioversionwarfarindabigatrancostsrhythm control. |
| spellingShingle | L. E. Kuvshinova N. V. Furman P. V. Dolotovskaya Ya. P. Dovgalevsky COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Рациональная фармакотерапия в кардиологии atrial fibrillation cardioversion warfarin dabigatran costs rhythm control. |
| title | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE |
| title_full | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE |
| title_fullStr | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE |
| title_full_unstemmed | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE |
| title_short | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE |
| title_sort | comparison of direct costs of dabigatran and warfarin therapy in patients with non valvular atrial fibrillation during preparation for elective cardioversion in the real clinical practice |
| topic | atrial fibrillation cardioversion warfarin dabigatran costs rhythm control. |
| url | https://www.rpcardio.online/jour/article/view/98 |
| work_keys_str_mv | AT lekuvshinova comparisonofdirectcostsofdabigatranandwarfarintherapyinpatientswithnonvalvularatrialfibrillationduringpreparationforelectivecardioversionintherealclinicalpractice AT nvfurman comparisonofdirectcostsofdabigatranandwarfarintherapyinpatientswithnonvalvularatrialfibrillationduringpreparationforelectivecardioversionintherealclinicalpractice AT pvdolotovskaya comparisonofdirectcostsofdabigatranandwarfarintherapyinpatientswithnonvalvularatrialfibrillationduringpreparationforelectivecardioversionintherealclinicalpractice AT yapdovgalevsky comparisonofdirectcostsofdabigatranandwarfarintherapyinpatientswithnonvalvularatrialfibrillationduringpreparationforelectivecardioversionintherealclinicalpractice |